Eficiência do cotratamento com RNA de interferência e tamoxifeno no câncer de mama
Loading...
Date
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Breast cancer was the second most common type of neoplasia in 2020 and
caused the highest mortality rate among women. Tamoxifen (TMX) is the most used
drug in hormone therapy against breast cancer. Over time, a drop in the effectiveness
of the drug has been observed due to the emergence of resistance on the part of cancer
cells. On the other hand, some studies claim that silencing of HOXB7 gene resensitizes
breast cancer cells resistant to TMX. HOXB7 silencing can be achieved through
targeted therapies, such as RNA interference therapy (RNAi), which consists of mRNA
degradation through specific pairing of small interfering RNA molecules (siRNA).
However, effective delivery of these small molecules depends on transfection agents
such as nanoparticles. Thus, the objective of this thesis was to evaluate the in vitro and
in vivo delivery efficiency of siRNA molecules from hybrid nanoparticles and to evaluate
the antitumor activity of HOXB7 gene silencing with and without co-treatment with TMX.
PEG-coated calcium phosphate (NP) nanoparticles were produced by self-association
of constituents. The NP had approximately 74 nm with a PdI of 0,1, a rounded and
homogeneous morphology and an encapsulation efficiency of 50%. Furthermore, the
NP remained stable for at least 180 days if stored at 4 °C and after freeze-drying
(p>0.05). Also, they were immediately resistant to temperatures of up to 40 °C and
faced disassociation in acidic conditions. Furthermore, NP encapsulating siRNA
complementary to the HOXB7 gene (NP-siHOXB7) promoted a slight reduction in cell
viability in 24 h (p<0.05), while empty NP (NP-mock) was not cytotoxic (p>0.05). The
migratory potential of cells after NP-siHOXB7 treatment was significantly reduced
(p<0.05) after 24 h. These last two results were corroborated by significant silencing of
the GFP gene in transformed lung cancer cells (p<0.05). The nanoformulation did not
present hemolytic activity (p>0.05). No difference in size and PdI were observed after
NP purification (p>0.05). In an orthotopic and xenographic breast tumor model in mice,
HOXB7 gene silencing of 50% was observed in tumor tissue. Although no significant
difference in tumor volume was observed between the groups treated in 14 days at the
concentration tested, there was no loss of individuals in the co-treatment group, unlike
the control group. Additionally, the evaluation of hematological and biochemical
parameters shows that TMX treatment was slightly toxic. Given these results, it can be
inferred that the nanocarrier was considered efficient in delivering siRNA both in cells
and in animal models and is a promising candidate for intravenous delivery of genetic
material. A larger sample size and variation in test concentration must be considered
to expand the antitumor effect analysis promoted by HOXB7 gene silencing and its cotreatment with TMX.
Description
Keywords
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

